The following excerpt is from the company's SEC filing.
On September 4, 2013, MiMedx Group, Inc., (the "Company") issued a press release addressing a letter received from the Food and Drug Administration (FDA) and reiterating its 2013 and 2014 guidance. Specifically, the Company stated its disagreement with the FDA letter, and indicated it does not expect the letter to impact its expected revenue range for 2013 of $54 million to $60 million or its 2014 goal of $90 million to $110 million.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever MiMedx Group, Inc.
makes a similar move, sign up!